Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2024

Description

Lung Cancer Diagnostics Market Growth & Trends:

The global lung cancer diagnostics market is expected to reach USD 7.26 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.

Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.

Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.

Lung Cancer Diagnostics Market Report Highlights:

The non-small cell lung cancer (NSCLC) segment dominated with a substantial revenue share in 2023. NSCLC is further trifurcated into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
EGFR mutation tests dominated the market with a 29.2% market share for 2023. Epidermal Growth Factor Receptor (EGFR) is one of the most prevalent actionable mutations in patients with NSCLC.
The hospitals and clinics segment dominated the market in 2023. This is attributed to the facilities with superior diagnostic tools and imaging technologies accounting for accurate lung cancer detection and staging.
North America dominated the global lung cancer diagnostics market in 2023 due to its advanced healthcare infrastructure, high healthcare spending, and strong reimbursement regulations for cancer diagnostics.

Product Code: 978-1-68038-888-6

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Lung Cancer Diagnostics Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Lung Cancer Diagnostics Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social Landscape
  - 3.4.2.3. Technological Landscape
  - 3.4.2.4. Environmental Landscape
  - 3.4.2.5. Legal Landscape

Chapter 4. Lung Cancer Diagnostics Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Lung Cancer Diagnostics Market: Type Movement Analysis, USD Billion, 2023 & 2030
4.3. Non-small Cell Lung Cancer
- 4.3.1. Non-small Cell Lung Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Small Cell Lung Cancer
- 4.4.1. Small Cell Lung Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Lung Cancer Diagnostics Market: Test Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Lung Cancer Diagnostics Market: Test Movement Analysis, USD Million, 2023 & 2030
5.3. CA Tests
- 5.3.1. CA Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. HER2 Tests
- 5.4.1. HER2 Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. ALK Tests
- 5.5.1. ALK Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Angiogenesis Inhibitors
- 5.6.1. Angiogenesis Inhibitors Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. EGFR Mutation Tests
- 5.7.1. EGFR Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. KRAS Mutation Tests
- 5.8.1. KRAS Mutation Tests Vision Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Lung Cancer Diagnostics Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Lung Cancer Diagnostic Market: End Use Movement Analysis, USD Million, 2023 & 2030
6.3. Hospitals and clinics
- 6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Diagnostic Laboratories
- 6.4.1. Diagnostics Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Others
- 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Lung Cancer Diagnostics Market: Regional Estimates & Trend Analysis

7.1. Lung Cancer Diagnostics Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
- 7.2.1. North America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. China
  - 7.4.2.1. China Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Japan
  - 7.4.3.1. Japan Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Australia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Saudi Arabia Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. UAE
  - 7.6.3.1. UAE Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. South Africa
  - 7.6.4.1. South Africa Lung Cancer Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. F. Hoffmann-La Roche Ltd
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Thermo Fisher Scientific
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Illumina Inc.
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Agilent Technologies
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Qiagen
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Abbott
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Bio-Rad
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Neogenomics Laboratories
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. bioMerieux
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Myriad Genetics, Inc
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives

Lung Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Small Cell Lung Cancer, Non-Small Cell Lung Cancer), By Test (CA Tests, HER2 Tests, ALK Tests), By End Use, Region And Segment Forecasts, 2024 - 2030